Furthermore, it has been shown that tocilizumab has an excellent ability to suppress serum amyloid A levels and could therefore be an important therapeutic strategy in amyloid A amyloidosis secondary to rheumatic diseases [6, 7].
Sample text:```The inter-relationships between K1, K1O and anticoagulants in dogs and humans have been previously investigated [25, 26].```
Sample intent: background
Sample text:```These results are in line with morphological abnormalities in a rabbit model of pneumococcal meningitis [8, 47], in neonatal and adult rat models [7, 51] and in human autopsy cases [20].```
Sample intent: result



Sample text:```Our results confi rm previous studies that reached the same conclusion (Boushey et al 1994; Vermeulen et al 2000; Till et al 2005; Marcucci et al 2005).```
Sample intent: result



Sample text:```Our results show that after 4 h of thiotepa treatment, the level of expression of anti-apoptotic Bcl-2 was not changed; this confirms the results of a previous study [25].```
Sample intent: result



Sample text:```Intriguingly, using MPRs-deficient MEF cells, mouse and human CLN5 have been shown to reach lysosomes in an MPRindependent manner [12].```
Sample intent: background



Sample text:```…et al., 1981; Kopp et al., 1992; Tiruppathi et al., 1996; Blazejewski et al., 1997), a glycoprotein that has been shown to be involved in protein binding (especially of albumin) in other epithelia (Kopp et al., 1992; Blazejewski et al., 1997), could perform this function at the blood–CSF interface.```
Sample intent: method
Sample text:```In addition, consistent with the result of our preclinical study, recent clinical study showed that alectinib was also highly active against ALK-positive NSCLC patients after treatment with crizotinib [21].```
Sample intent: result



Sample text:```Other studies suggest that altering affinity to FcRn might alter the bioavailability of mAbs (Deng et al., 2010; Deng et al., 2012), and SC bioavailability appears lower in FcRn-deficient mice as compared to wild type animals (Wang et al., 2008).```
Sample intent: method



Sample text:```The inter-relationships between K1, K1O and anticoagulants in dogs and humans have been previously investigated [25, 26].```
Sample intent: background



Sample text:```In our previous study, we found that RAG-mediated nicking and cleavage of oligonucleotide substrates containing cRSSs identified from lymphoid malignancies were either unchanged or slightly reduced in the presence of HMGB1 for most cRSSs tested (including LMO2, TAL1, Hox11, SIL, SCL), except Ttg-1 [24].```
Sample intent: method



Sample text:```Trials were considered eligible if they satisfied the following inclusion criteria: (1) RCTs comparing RIC versus no conditioning in patients with AMI; (2) patients were treated by primary PCI or thrombolysis; (3) RIC was induced by intermittent limb ischemia–reperfusion; and (4) trials at least reported one of the following outcome measures, including enzymatic myocardial infarction size as assessed by serum peak creatine```
Sample intent: background



Sample text:```Pupillometry has been proposed as a simple and sensitive tool to detect subclinical autonomic dysfunction [30,31].```
Sample intent: background



Sample text:```In line with our results, several previous studies demonstrated the anti-proliferative effect of PPARs agonists in several cell types [11-15].```
Sample intent: result



Sample text:```Our results show that after 4 h of thiotepa treatment, the level of expression of anti-apoptotic Bcl-2 was not changed; this confirms the results of a previous study [25].```
Sample intent: result



Sample text:```…et al., 1981; Kopp et al., 1992; Tiruppathi et al., 1996; Blazejewski et al., 1997), a glycoprotein that has been shown to be involved in protein binding (especially of albumin) in other epithelia (Kopp et al., 1992; Blazejewski et al., 1997), could perform this function at the blood–CSF interface.```
Sample intent: method



Sample text:```Importantly, brain atrophy measures based on T1w images are shown to correlate with the amount of tau deposition and neuropsychological deficits, thus validating its use as a biomarker of Alzheimer’s disease (AD) (Frisoni et al., 2010).```
Sample intent: method